Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
OBJECTIVE
To evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor (CAG) regimen for refractory biphenotypic acute leukemia (BAL).


METHODS
We treated 5 refractory BAL patients by CAG regimen (10 mg x m(-2) cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg x m(-2) aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 microg x m(-2) x d(-1) granulocyte colony-stimulating factor subcutaneously) from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured.


RESULTS
The complete remission rate was 80%, median duration of absolute neutrophil count < 5.0 x 10(8)/L and platelet count < 2.0 x 10(10)/L was day 13 and day 1, respectively; and the infection rate was low (III-IV infection rate, 20.00%).


CONCLUSIONS
CAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.
He
Guang-Sheng
GS
Jiangsu Insititute of Hematology, the First Affiliated Hospital of Soochow University, Thrombosis and Hemostasis Key Laboratory of Ministry of Health of Soochow University, Suzhou 215006, China.
Zhang
Xiang
X
Wu
De-Pei
DP
Sun
Ai-Ning
AN
Jin
Zheng-Ming
ZM
Qiu
Hui-Ying
HY
Miao
Miao
M
Tang
Xiao-Wen
XW
Fu
Zheng-Zheng
ZZ
Han
Yue
Y
D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015456:Leukemia, Biphenotypic, Acute / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction; D016896:Treatment Outcome; D055815:Young Adult
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D015250:Aclarubicin